Dataset Information

Bioengineering of the implantable vascularized endocrine constructs for insulin delivery suitable for clinical upscaling

ABSTRACT: Beta cell replacement therapy for type 1 diabetes is hindered by poor graft survival and suboptimal function, largely due to inadequate vascularization and lack of supportive microenvironment. To address these challenges, we developed a clinically scalable, extracellular matrix (ECM)–mimetic hydrogel, termed Amniogel, derived from human amniotic membrane via streamlined, clinically compliant process. Co-encapsulation of pancreatic islets with blood outgrowth endothelial cells (BOECs) within Amniogel facilitated the formation of prevascularized endocrine constructs (VECs).

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Placenta

SUBMITTER: Fanny Lebreton

LAB HEAD: Ekaterine Berishvili

PROVIDER: PXD063772 | Pride | 2026-04-24

REPOSITORIES: pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20190429_QE25CM114_pl19038_KBellofatto_01.raw	Raw
	20190429_QE25CM114_pl19038_KBellofatto_01__F010288_.mzid	Mzid
	20190429_QE25CM114_pl19038_KBellofatto_01__F010288_.mzid_20190429_QE25CM114_pl19038_KBellofatto_01__F010288_.MGF	Mzid
	20190429_QE25CM116_pl19038_KBellofatto_02.raw	Raw
	20190429_QE25CM116_pl19038_KBellofatto_02__F010289_.mzid	Mzid

Items per page:

1 - 5 of 16

Similar Datasets

Project description:Ovarian cancer is a major cause of cancer mortality among women largely due to late diagnosis of advanced stage metastatic disease. More extensive molecular analysis of metastatic ovarian cancer is needed to identify post-translational modifications of proteins particularly associated with metastatic disease so that we can better understand the metastatic process and identify potential therapeutic targets. Proteins are the target of many recently developed cancer treatments, but an often neglected aspect of biomarker discovery is protein glycosylation, especially those involving tumor-associated carbohydrate antigens (TACAs) such as sialyl-Lewis(x) (SLe(x) and sialyl-Lewis(a) (SLe(a), which have been identified in various cancers. Although it is already known that considerable changes in protein glycosylation are major contributors to the initiation, progression and metastasis of tumors, specifics about glycosylation changes particularly important to the metastatic process are still lacking. In this report we describe the results of a combined glycomic and proteomic study of metastatic ovarian cancer (OC) ascites fluids. Glycoproteins in ascites fluid were enriched by affinity binding to lectins (ConA or WGA) and other affinity matrices. Separate glycomic and proteomic analyses were performed as well as glycopeptide analyses. Relative abundances of different N-glycan groups and proteins were identified from original ascites fluids and corresponding lectin bound samples. Levels of biomarkers CA125, MUC1 and fibronectin were also monitored in these samples by Western blot analysis. N-glycan analysis of ascites fluids showed the presence of large, highly fucosylated and sialylated, complex and hybrid glycans, some of which were not observed in normal serum. Proteins in OC ascites that were more abundant or not present in the serum control, were haptoglobin, fibronectin, lumican, fibulin, hemopexin, ceruloplasmin, alpha-1-antitrypsin and alpha-1-antichymotrypsin. Glycopeptide analysis identified N- and O-glycans in clusterin, hemopexin, and fibulin that were present in OC ascites.

Dataset Information

Bioengineering of the implantable vascularized endocrine constructs for insulin delivery suitable for clinical upscaling

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets